193 related articles for article (PubMed ID: 26808114)
1. Clinicopathological factors predictive of postoperative seizures in patients with gliomas.
Yang P; Liang T; Zhang C; Cai J; Zhang W; Chen B; Qiu X; Yao K; Li G; Wang H; Jiang C; You G; Jiang T
Seizure; 2016 Feb; 35():93-9. PubMed ID: 26808114
[TBL] [Abstract][Full Text] [Related]
2. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
[TBL] [Abstract][Full Text] [Related]
3. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
4. Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas: a report of 198 patients from China.
Yang P; You G; Zhang W; Wang Y; Wang Y; Yao K; Jiang T
Seizure; 2014 Nov; 23(10):844-51. PubMed ID: 25153654
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
6. The expression of p53, mgmt and egfr in brain glioma and clinical significance.
Lin T; Wang M; Liang HS; Liu EZ
J Biol Regul Homeost Agents; 2015; 29(1):143-9. PubMed ID: 25864751
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
8. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
9. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study.
You G; Sha ZY; Yan W; Zhang W; Wang YZ; Li SW; Sang L; Wang Z; Li GL; Li SW; Song YJ; Kang CS; Jiang T
Neuro Oncol; 2012 Feb; 14(2):230-41. PubMed ID: 22187341
[TBL] [Abstract][Full Text] [Related]
10. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience.
Schlosser S; Wagner S; Mühlisch J; Hasselblatt M; Gerss J; Wolff JE; Frühwald MC
Pediatr Blood Cancer; 2010 Feb; 54(2):228-37. PubMed ID: 19856394
[TBL] [Abstract][Full Text] [Related]
11. An extent of resection threshold for seizure freedom in patients with low-grade gliomas.
Xu DS; Awad AW; Mehalechko C; Wilson JR; Ashby LS; Coons SW; Sanai N
J Neurosurg; 2018 Apr; 128(4):1084-1090. PubMed ID: 28548599
[TBL] [Abstract][Full Text] [Related]
12. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
13. Seizure characteristics and control following resection in 332 patients with low-grade gliomas.
Chang EF; Potts MB; Keles GE; Lamborn KR; Chang SM; Barbaro NM; Berger MS
J Neurosurg; 2008 Feb; 108(2):227-35. PubMed ID: 18240916
[TBL] [Abstract][Full Text] [Related]
14. [A molecular classification system for anaplastic glioma].
Jiang HH; Ren XH; Zhang Z; Lin S
Zhonghua Wai Ke Za Zhi; 2013 Dec; 51(12):1104-9. PubMed ID: 24499721
[TBL] [Abstract][Full Text] [Related]
15. [The clinical research of the MGMT expression levels in glioma pations].
Xia HC; Zhu ZQ; Liu L; Tian HL; Sun Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Aug; 25(4):265-7. PubMed ID: 22097602
[TBL] [Abstract][Full Text] [Related]
16. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
17. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Wu PF; Kuo KT; Kuo LT; Lin YT; Lee WC; Lu YS; Yang CH; Wu RM; Tu YK; Tasi JC; Tseng HM; Tseng SH; Cheng AL; Lin CH
Lung Cancer; 2010 Jun; 68(3):484-90. PubMed ID: 19740564
[TBL] [Abstract][Full Text] [Related]
18. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
19. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of P53, O6-methylguanine-dna methyltransferase and epidermal growth factor receptor in glioma.
Fu XR; Sun ZC; Chang Y
J Biol Regul Homeost Agents; 2015; 29(4):853-8. PubMed ID: 26753647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]